NEU

2.81%

$18.65 neuren pharmaceuticals limited

Success in Phase 1 Alzheimer's trial adds $40 bn, page-5

First 5 Last

Share
Profile

Follow
mjc159

1,543 Posts.

164

23/03/15

15:58

Post #: 14963172
Share

Originally posted by hottod ↑

If nothing else, the Biogen story shows that the market loves therapies with successful trials in neurological conditions where there is a large market with unmet need.

Alzheimer’s is perhaps the most obvious condition in this category as it taps into the aging Baby Boomer market. There are estimated to be more than 5 million Americans with Alzheimer’s, with the annual incidence in the US estimated to be approximately 470,000.

But there are also other neurological conditions with large markets of unmet need.

Traumatic brain injury is one. In the United States the estimated annual incidence of TBI (a condition with no current treatment) is 1.7 million. Neuren’s Phase 2 results of NNZ-2566 in both mild and moderate to severe TBI should be known by later this year. With Neuren’s current shareprice at .10, the market doesn’t seem to be anticipating trial success. But what if the trials do demonstrate efficacy? What if the drug demonstrates not only efficacy, but also a better safety profile than Biogen’s drug?

It’s also worth remembering Neuren’s second drug, NNZ-2591, which is currently being prepared for IND submission. It has already demonstrated efficacy in pre-clinical models of stroke. The estimated annual incidence of stroke in the US is 800,000 – higher than Alzheimer’s. Finally, it shouldn't be forgotten that the patent for NNZ-2591, issued last year with respect to “improvement of cognitive performance in impaired animals”, also makes claim for treatment of Alzheimer’s Disease, Dementia, Parkinson’s Disease and age-related memory loss (along with other conditions).

Expand

Thanks hottod

Do you have any numbers on the incidence of age-related memory loss. From personal experience, it starts to kick-in around 40.
"Where did I put my car keys again?"

NEU Price at posting: 10.0¢ Sentiment: Hold Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

DVP

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

MGU

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

VMS

Venture to sniff out high-grade REE targets at Jupiter project, WA

NXG

Cost blow-out for Rook I uranium project sees share plummet for NexGen

VMT

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

GRX

GreenX picks up prospective copper project in Germany

BOE

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Is oil undervalued?

WGX

Westgold sets its sights on top five producer status through merger with Karora

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

There are more pages in this discussion • 2 more messages in this thread...

First 5 Last

Add NEU (ASX) to my watchlist

(20min delay)
Last $18.65		Change -0.540(2.81%)		Mkt cap ! $2.383B

Open	High	Low	Value	Volume
$18.98	$19.15	$18.50	$10.51M	560.3K

Buyers (Bids)

No.	Vol.	Price($)
1	1500	$18.62

Sellers (Offers)

Price($)	Vol.	No.
$18.65	1127	2

View Market Depth

No.	Vol.	Price($)
1	810	18.530
4	1225	18.510
7	2678	18.500
2	1169	18.490
1	162	18.450

Price($)	Vol.	No.
19.080	300	1
19.150	150	1
19.200	899	2
19.240	550	1
19.340	1000	1

Last trade - 16.10pm 02/08/2024 (20 minute delay)

NEU (ASX) Chart

Success in Phase 1 Alzheimer's trial adds $40 bn, page-5

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Venture to sniff out high-grade REE targets at Jupiter project, WA

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

GreenX picks up prospective copper project in Germany

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Is oil undervalued?

Westgold sets its sights on top five producer status through merger with Karora

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Success in Phase 1 Alzheimer's trial adds $40 bn, page-5

Top Stories

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Venture to sniff out high-grade REE targets at Jupiter project, WA

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

GreenX picks up prospective copper project in Germany

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Is oil undervalued?

Westgold sets its sights on top five producer status through merger with Karora

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News